Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

47.90 +2.80 (+6.21%)
Streaming Delayed Price Updated: 3:14 PM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 25,204,728
Open 46.00
Bid (Size) 47.90 (8)
Ask (Size) 47.91 (9)
Prev. Close 45.10
Today's Range 45.64 - 48.58
52wk Range 42.96 - 63.33
Shares Outstanding 2,222,113,553
Dividend Yield 5.18%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
In today's session, there are S&P500 stocks with remarkable trading volume.
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session. 
Via Chartmill
Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday?
Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat. 
Via Benzinga

Performance

YTD
-15.7%
-15.7%
1 Month
+1.0%
+1.0%
3 Month
+0.8%
+0.8%
6 Month
-19.6%
-19.6%
1 Year
-7.4%
-7.4%

More News

Read More
Why Is Bristol-Myers Squibb (BMY) Stock Rocketing Higher Today
Via StockStory
Topics Artificial Intelligence
Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026
Via Stocktwits
Bristol Myers Announces Positive Outcomes From Multiple Myeloma Late-Stage Study
Via Stocktwits
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease
From Bristol Myers Squibb
Via Business Wire
Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge
Via MarketMinute
Topics Economy Government World Trade
Trump's Plan To Lower U.S. Drug Prices Faces Big Test
Via Investor's Business Daily
Topics Government
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Via MarketMinute
Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Program
Via Stocktwits
Topics Government
Johnson & Johnson's Hypothetical Rally: A Look at Potential 2025 Valuation Drivers
Via MarketMinute
Topics Economy Intellectual Property
Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data
Via MarketMinute
Trump's 100% Drug Tariffs 'A Meaningful Commercial Hit' For Americans, But 'Loopholes' Could Blunt Impact, Says Analyst
Via Benzinga
Topics Government World Trade
Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Via Benzinga
Topics Government World Trade
Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)
From Bristol Myers Squibb
Via Business Wire
The Smartest Dividend Stock to Buy With $1,000 Right Now
Via The Motley Fool
Topics Intellectual Property
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Via The Motley Fool
Topics Intellectual Property
Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients
Via Benzinga
Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
1 Reason to Buy Bristol Myers Squibb Stock
Via The Motley Fool
Topics Intellectual Property
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Via MarketMinute
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Via MarketMinute

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 47.90
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 10/01/25 03:14 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 106.44B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 106B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.